Navigation Links
International Federation of Sports Medicine Selects Celadrin(R) Topical Cream as it's First and Only Official Joint and Muscle Topical Cream
Date:2/25/2008

ors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services. These factors and others could cause operating results to vary significantly from those in prior periods and those projected in forward-looking statements. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in certain forms the company has filed and will periodically file with the Securities Exchange Commission.


'/>"/>
SOURCE Imagenetix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. 2008 International Stroke Conference Highlights Impact of Merci Retrieval System
2. Pezcoller Foundation-AACR International Award for Cancer Research recognizes Axel Ullrich
3. Logistical information for the 2008 International Stroke Conference
4. China Dongsheng International Announces Fiscal Year 2008 Second Quarter Financial Results
5. ASA International Stroke Conference 2008
6. DATATRAK International Management to Host Conference Call on February 26, 2008 to Discuss Fourth Quarter and Full Year Operating Results for 2007
7. ORBIS Internationals Flying Eye Hospital Returns to Myanmar
8. Global Med Technologies(R), Inc. Adds Internationally Renowned NewYork- Presbyterian Hospital to Client List
9. Tahitian Noni International Expands HIRO(TM) Beverage Line With Super Fruits Sparkling Black Currant
10. Service Corporation International Declares Quarterly Cash Dividend
11. Healthy Coffee International, Inc. Establishes Healthy Coffee USA, Inc. as Its Marketing Arm
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 2Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 3Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 4Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 5Health News:Pitt study suggests craving hinders comprehension without your realizing it 2Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 2Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 3Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 4Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 5Health News:Wellness Cruise Offers Crystal Guests 'Indian Ocean Insight' 2Health News:VitaminSpice Signs Agreement With Former CEO of Wal-Mart Stores Division for US Distribution 2
Breaking Medicine Technology:VidaySalud.com(TM) Reaches 1,000,000 Page Views In its First Six Months of Operation 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 2Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 3New Certification Commission for Healthcare Interpreters Opens Doors to Improve Provider Patient Communication 26 Quality Medical Care 57223 1New Certification Commission for Healthcare Interpreters Opens Doors to Improve Provider Patient Communication 26 Quality Medical Care 57223 2New Certification Commission for Healthcare Interpreters Opens Doors to Improve Provider Patient Communication 26 Quality Medical Care 57223 3Biosimilars of Rituxan MabThera Herceptin and Erbitux will Erode 248 2 Billion in U S and European Sales in 2018 57220 1Biosimilars of Rituxan MabThera Herceptin and Erbitux will Erode 248 2 Billion in U S and European Sales in 2018 57220 2Biosimilars of Rituxan MabThera Herceptin and Erbitux will Erode 248 2 Billion in U S and European Sales in 2018 57220 3People With Swine Flu May Be Contagious Longer Than Thought 57217 1People With Swine Flu May Be Contagious Longer Than Thought 57217 2People With Swine Flu May Be Contagious Longer Than Thought 57217 3